Jump to content

Talk:COVID-19 drug repurposing research

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by TWM03 (talk | contribs) at 18:31, 20 October 2021 (FDA tweet). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.



Treatments for COVID-19: Current consensus

A note on WP:MEDRS: Per this Wikipedia policy, we must rely on the highest quality secondary sources and the recommendations of professional organizations and government bodies when determining the scientific consensus about medical treatments.

  1. Ivermectin: The highest quality sources (1 2 3 4) suggest Ivermectin is not an effective treatment for COVID-19. In all likelihood, ivermectin does not reduce all-cause mortality (moderate certainty) or improve quality of life (high certainty) when used to treat COVID-19 in the outpatient setting (4). Recommendations from relevant organizations can be summarized as: Evidence of efficacy for ivermectin is inconclusive. It should not be used outside of clinical trials. (May 2021, June 2021, June 2021, July 2021, July 2021) (WHO, FDA, IDSA, ASHP, CDC, NIH)
  2. Chloroquine & hydroxychloroquine: The highest quality sources (1 2 3 4) demonstrate that neither is effective for treating COVID-19. These analyses accounted for use both alone and in combination with azithromycin. Some data suggest their usage may worsen outcomes. Recommendations from relevant organizations can be summarized: Neither hydroxychloroquine nor chloroquine should be used, either alone or in combination with azithromycin, in inpatient or outpatient settings. (July 2020, Aug 2020, Sep 2020, May 2021) (WHO, FDA, IDSA, ASHP, NIH)
  3. Ivmmeta.com, c19ivermectin.com, c19hcq.com, hcqmeta.com, trialsitenews.com, etc: These sites are not reliable. The authors are pseudonymous. The findings have not been subject to peer review. We must rely on expert opinion, which describes these sites as unreliable. From published criticisms (1 2 3 4 5), it is clear that these analyses violate basic methodological norms which are known to cause spurious or false conclusions. These analyses include studies which have very small sample sizes, widely different dosages of treatment, open-label designs, different incompatible outcome measures, poor-quality control groups, and ad-hoc un-published trials which themselves did not undergo peer-review. (Dec 2020, Jan 2021, Feb 2021)

Last updated (diff) on 27 February 2023 by Sumanuil (t · c)

Extended-confirmed-protected edit request on 16 September 2021

Suggest that the following conclusion from "Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVOC-19" appearing in the American Journal of Therapeutics (2021)be added:

The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit. . . . Overall, the evidence also suggests that early use of ivermectin may reduce morbidity and mortality from COVID-19. This is based on (1) reductions in COVID-19 infections when ivermectin was used as prophylaxis, (2) the more favorable effect estimates for mild to moderate disease compared with severe disease for death due to any cause, and (3) on the evidence demonstrating reductions in deterioration. 2601:189:C480:FFB0:0:0:0:CFEE (talk) 19:06, 16 September 2021 (UTC)[reply]

 Not done for now: please establish a consensus for this alteration before using the {{edit extended-protected}} template. This will be "a whole thing." I suggest you seek consensus here on the talk page for that addition. ScottishFinnishRadish (talk) 19:16, 16 September 2021 (UTC)[reply]

Extended-confirmed-protected edit request on 18 September 2021

I think this article deserves to be included. It is a well sourced and reputable newspaper in India. It writes how the State with the highest population in India used Ivermectin to treat Covid-19 and how it was sanctioned by the State's Health Department.

Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low The 13th 4postle (talk) 15:14, 18 September 2021 (UTC)[reply]

 Not done. Re: India, we already discuss this with other sources that are more recent. Sub-topic discussion of just Uttar Pradesh would be WP:UNDUE. — Shibbolethink ( ) 15:39, 18 September 2021 (UTC)[reply]

Extended-confirmed-protected edit request on 5 October 2021

Change “After reviewing the evidence on ivermectin, the European Medicines Agency (EMA) advised against it's use” to “After reviewing the evidence on ivermectin, the European Medicines Agency (EMA) advised against its use”

Remove incorrect apostrophe DarthTaper (talk) 00:23, 5 October 2021 (UTC)[reply]

 Done Firefangledfeathers (talk) 00:27, 5 October 2021 (UTC)[reply]

FDA tweet

Twitter is not a reliable source, and the informal wording suggests it is not supposed to be taken as an official statement by the FDA. Quoting the tweet without the context of the article that was attached to it is potentially misleading about the scientific reasons for opposing the treatment. Should we remove the tweet? TWM03 (talk) 17:58, 20 October 2021 (UTC)[reply]

I think it should stay. It's a tweet from an official US federal government agency. The article doesn't provide much more context; it's pretty much just "Stop it." Firefangledfeathers (talk) 18:07, 20 October 2021 (UTC)[reply]
Shouldn't we at least link to the article as per WP:HEADLINE? TWM03 (talk) 18:30, 20 October 2021 (UTC)[reply]